Evidence map›Paper›PMID 35267408›Full record

ArticleCancers2022

Therapeutic Potential of Certain Terpenoids as Anticancer Agents: A Scoping Review.

Sareh Kamran, Ajantha Sinniah, Mahfoudh A M Abdulghani, Mohammed Abdullah Alshawsh

Open access · goldAbstract readScoping Review
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed
17.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 221 citations in OpenAlex.

  1. Review
  2. β-Thujaplicin modulates the ODC-ROS-linked apoptosis in H460 lung cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  3. Terpenoids as modulators of autophagy-senescence crosstalk in lung cancer.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  4. Phytochemical Profile and Bioactive Potential ofAntioxidants (Basel, Switzerland) · 2026
    Article
  5. Review
  6. Review
  7. The Protective Potential of Terpenoid-RichJournal of cancer prevention · 2026
    Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Sareh KamranDepartment of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia.
Ajantha SinniahDepartment of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia.ORCID 0000-0002-7572-9926
Mahfoudh A M AbdulghaniDepartment of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Al Qassim 51911, Saudi Arabia.
Mohammed Abdullah AlshawshDepartment of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia.ORCID 0000-0001-8342-5183
University of Malaya · MYQassim University · SA

Funding

FRGS research grant, Ministry of Higher Education, Malaysia (FP103-2019A), Ref: (FRGS/1/2019/SKK10/UM/02/3)
6 · The paper itself

Abstract

Cancer is a life-threatening disease and is considered to be among the leading causes of death worldwide. Chemoresistance, severe toxicity, relapse and metastasis are the major obstacles in cancer therapy. Therefore, introducing new therapeutic agents for cancer remains a priority to increase the range of effective treatments. Terpenoids, a large group of secondary metabolites, are derived from plant sources and are composed of several isoprene units. The high diversity of terpenoids has drawn attention to their potential anticancer and pharmacological activities. Some terpenoids exhibit an anticancer effect by triggering various stages of cancer progression, for example, suppressing the early stage of tumorigenesis via induction of cell cycle arrest, inhibiting cancer cell differentiation and activating apoptosis. At the late stage of cancer development, certain terpenoids are able to inhibit angiogenesis and metastasis via modulation of different intracellular signaling pathways. Significant progress in the identification of the mechanism of action and signaling pathways through which terpenoids exert their anticancer effects has been highlighted. Hence, in this review, the anticancer activities of twenty-five terpenoids are discussed in detail. In addition, this review provides insights on the current clinical trials and future directions towards the development of certain terpenoids as potential anticancer agents.

Indexed as

cancerchemosensitizationmolecular mechanismterpenesterpenoids

Identifiers

PMID35267408
PMCPMC8909202
OpenAlexW4214735603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.